Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRSA - Methicillin-resistant Staphylococcus aureus -- Ignore unavailable to you. Want to Upgrade?

To: Glenn Petersen who wrote (155)

4/30/2014 5:54:30 PM

From: zen_lunatic420

Respond to of 191

Covalon [COV.v/CVALF]: If an ounce of prevention is worth a pound of cure, then this company's stock should be worth more.

Covalon developed and patented a dual antimocrobial silicone adhesive bandage (chlorhexidine and silver) that was beginning to see some serious sales traction before they licensed it to Molnlycke Healthcare in November 2013 (the largest supplier of clear silicon adhesive bandages worldwide). Sales seam to have stalled in their Fiscal Q1 of 2014 (ending December 2013), but Molnlycke has already launched their product in February 2014 and the next few quarters should be telling of the market potential for these products.

Molnycke's website:
mepitelfilmam.com

Trailing Financial Performance

Fiscal Quarter	Wound Care Sales	Total Revenue	Earnings
Q3/2014
Q2/2014
Q1/2014	$733,590	$4,522,201	$3,120,419
Q4/2013	$1,352,855	$1,543,019	$125,319
Q3/2013	$1,411,220	$1,477,632	$234,826
Q2/2013	$478,371	$535,224	($558,831)
Q1/2013	$520,523	$578,268	($794,481)
Q4/2012	$502,715	$951,134	($1,854,874)
Q3/2012	$632,749	$1,085,791	($732,308)
Q2/2012	$524,247	$1,100,222	($604,146)

I completed a more complete overview of the company on the I-Hub message board:
siliconinvestor.com